

Invited Participants

ISPOR 13th Patient Representatives Roundtable – Europe

(Supported by Novartis, Pfizer, and Takeda)

Monday, 12 November 2018 – 12:15 – 16:45

Centre de Convencions Internacional de Barcelona

Barcelona, Spain

Patient Representatives:

Nicola Bedlington

Secretary General

European Patients' Forum (EPF)

Brussels, Belgium

Neil Bertelsen

Chair

HTAi Patient & Citizen Involvement in HTA Interest Group

Berlin, Germany

Anthony Berthon, PharmD

Patient representative

Française de l'Eczema

Les Cotes D'Arey, France

Jan Geissler

Chair, **ISPOR Patient Representatives Roundtable - Europe**

Co-founder, **CML Advocates Network**

Board Member, **Acute Leukemia Advocates Network**

Co-Chair FUTURES Team, **EUPATI**

CEO, **Patvocates**

Munich, Germany

Dominique Hamerlijnck

Patient Representative

Lung Foundation Netherlands (Longfonds)

Amersfoort, the Netherlands

Ivett Jakab

Patient advocate

Transplant Foundation

Budapest, Hungary

Joan Jordan

Patient Expert (EUPATI)

Multiple Sclerosis Society of Ireland

Dublin, Ireland

Paola Kruger

Patient Expert (EUPATI)

Accademia dei Pazienti Onlus Advocacy

Rome, Italy

Invited Participants

Robert McBurney, PhD, BSc

Chief Executive Officer, **Accelerated Cure Project for Multiple Sclerosis**
Founder and Director, **Optimal Medicine Ltd.**
Waltham, MA, USA

Derick Mitchell, PhD, BSc. (Hons)

Chief Executive
Irish Platform for Patient Organisations, Science & Industry (IPPOSI)
Dublin, Ireland

Kate Morgan

Policy and Public Affairs Manager
Myeloma Patients Europe (MPE)
Brussels, Belgium

John Paton

Ambassador
National Rheumatoid Arthritis Society
Scotland, United Kingdom

Ananda Plate

Chair, **WECAN (Workgroup of European Cancer Patient Advocacy Networks)**
CEO, **Myeloma Patients Europe**
Munich, Germany

Bettina Ryll, MD, PhD

Founder, **Melanoma Patient Network Europe (MPNE)**
Chair, Patient Advocates Working Group, **European Society for Medical Oncology (ESMO)**
Uppsala, Sweden

Suzanne Schrandt, JD

Chair, **ISPOR Patient Representative Roundtable – North America**
Director, Patient Engagement, **Arthritis Foundation**
Atlanta, GA, USA

Krisztina Kalone Toth

Patient Representative
Collaboration for Health Against Breast Cancer
Budapest, Hungary

Mirjami Tran Minh

Project Manager
Association of Cancer Patients in Finland
Helsinki, Finland

Invited Participants

Researcher/Academic

Tom Burke

Senior Health Economist
CHES study/HCD Economics Ltd.
Manchester, United Kingdom

Nancy Devlin, PhD

President-Elect (2019-2020), **ISPOR**
Director of Research, **Office of Health Economics (OHE)**
London, United Kingdom

Karen Facey, PhD

Honorary Research Fellow and Evidence Based Healthcare Policy Consultant
University of Edinburgh
Edinburgh, United Kingdom

Sandra Nestler-Parr, PhD, MSc

Managing Director, **Rare Access Ltd.**
Trustee, **Alpha-1 UK Support Group**
London, United Kingdom

Payer and HTA Stakeholder Participants

Margaret Galbraith

Scientific Project Manager
Haute Autorité de Santé (HAS)
Saint-Denis La Plaine, France

Claire Gorry, PhD Candidate

Pharmacist
National Centre for Pharmacoeconomics
Dublin, Ireland

Heidi Livingstone

Public Involvement Adviser
National Institute for Health and Care Excellence (NICE)
London, United Kingdom

Regulatory and Government Participants

Nathalie Bere

Patient Liaison Coordinator
European Medicines Agency (EMA)
London, United Kingdom

Flora Giorgio, PhD

Policy Officer, DG Sante
European Commission
Brussels, Belgium



Invited Participants

Industry Representatives:

Louise Huneault, BSN, Med

Head, Patient Relations Hematology, Region Europe

Novartis Pharma AG

Basel, Switzerland

Judith Luker, BA

International Alliance Development

Pfizer

London, United Kingdom

ISPOR Staff – Lawrenceville, NJ, USA

Nadia Naaman, Senior Director, Scientific & Health Policy Initiatives

Theresa Tesoro, MSN, Associate Director, Scientific & Health Policy Initiatives

Clarissa Cooblall, MPH, CHES, Manager, Scientific & Health Policy Initiatives